Bayer Ag · XETR:BAYN
Bayer — Technical Presentation (2026)
8 slides from Bayer's technical presentation, 2026
Slide 1: Finerenone and Serum Sodium in Patients with Heart Failure and Mildly Reduced or Preserved Ejection Fraction
Finerenone and Serum Sodium in Patients with Heart Failure and Mildly Reduced or Preserved Ejection Fraction: An Analysis of FINEARTS-HF Ryohei Ono, M.D. Ph.D. 1 on behalf of : Kieran Docherty, MBChB Ph.D.1; Alasdair D. Henderson, Ph.D.1; Brian L. Claggett, Ph.D.2; Akshay S. Desai, M.D. MPH2; Caroly
Slide 2: Background: Serum sodium in FINEARTS-HF
Background: Serum sodium in FINEARTS-HF • Serum sodium concentration is a fundamental marker of fluid homeostasis, and hyponatraemia is associated with adverse outcomes in heart failure (HF), particularly in HF with reduced ejection fraction; however, its prognostic significance in HF with preserved
Slide 3: Objectives and methods: Serum sodium in FINEARTS-HF
Objectives and methods: Serum sodium in FINEARTS-HF Finerenone Objectives HFmrEF N=3003 • To examine the distribution and prognostic HFpEF Placebo significance of serum sodium concentration, N=6001 N=2998 and the effects of finerenone on serum Primary endpoint sodium concentration and clinical The c
Slide 4: Baseline clinical characteristics by serum sodium category
Baseline clinical characteristics by serum sodium category Prevalence of hypernatraemia, normonatraemia, and hyponatraemia T1 T2 T3 P for Serum sodium tertile (T) Na 117-140 Na 141-142 Na 143-154 trend (n = 2,632) (n = 1,773) (n = 1,450) Age (years) 72 72 72 0.57 Hypernatraemia (≥145 mmol/L) Sex, ma
Slide 5: Clinical outcomes according to serum sodium tertile/level
Clinical outcomes according to serum sodium tertile/level Total HF events and CV death Total HF events CV death Mean cumulative events Cumulative incidence (%) Mean cumulative events (per 100 patients) (per 100 patients) Total TotalHF HFevents eventsand andCV CVdeath death TotalHFHFevents Total even
Slide 6: Effect of finerenone on serum sodium during follow-up
Effect of finerenone on serum sodium during follow-up Change in serum Na+ concentration after randomization Serum sodium (mmol/L) Placebo Finerenone Mean difference (Finerenone – Placebo) 1 month: -0.9 (-1.1 to -0.8) mmol/L 3 months : -1.1 (-1.2 to -0.9) mmol/L Months after randomization
Slide 7: Effect of finerenone on CV death and HF events according to Na+ level
Effect of finerenone on CV death and HF events according to Na + level Tertile 1 (Na+ 117-140 mmol/L) Tertile 2 (Na+ 141-142 mmol/L) Tertile 3 (Na+ 143-154 mmol/L) Interaction (n = 2,632) (n = 1,773) (n = 1,450) P value Finerenone Placebo Finerenone Placebo Finerenone Placebo (n = 1,295) (n = 1,337)
Slide 8: Conclusions: Serum sodium in FINEARTS-HF
Conclusions: Serum sodium in FINEARTS-HF • Hyponatraemia (≤135 mmol/L) was uncommon (4.6%) at baseline in FINEARTS-HF. • Treatment with finerenone led to only a small (approximately 1 mmol/L) reduction in serum sodium concentration during follow-up. • The benefits of finerenone were consistent acros